A comparison of EULAR and GRAPPA recommendations for psoriatic arthritis management

Primary tabs

NEWS
A comparison of EULAR and GRAPPA recommendations for psoriatic arthritis management

Psoriatic arthritis (PsA) is a form of arthritis typicallly affecting people with psoriasis and is indicated by red patches on the skin with silver scales.Common symptoms of persisting PsA include joint pain, immobility of joints and inflammation. Early diagnosis is crucial to avoid damage to the joints and further complications. Many therapeutic agents are now accessible for PsA, but treatment decisions are not always straightforward.

To aid in the decision making process, two sets of recommendations for the management of PsA were published in 2016 by international organizations — The European League Against Rheumatism (EULAR) and The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The EULAR is the organisation representing the people with arthritis/rheumatism, health professional and scientific societies of rheumatology of all the European nations. As for GRAPPA, it has pulled together many different groups, including preeminent researchers and thought-leaders in PsA and psoriasis.

Coming on to the two sets of recommendations,  the heterogeneity of PsA is perceived and the place of various drugs in the therapeutic armamentarium is discussed. Such agents comprise of conventional disease-modifying antirheumatic drugs (DMARDs), like methotrexate, and targeted therapies including biologic agents, like ustekinumab, secukinumab and the tumor necrosis factor (TNF) inhibitors, or the targeted synthetic drug apremilast. The proposed sequential use of these drugs and some other aspects of PsA management vary between the two sets of recommendations. This discrepancy is partly the result of a difference in the evaluation process. The highlight of EULAR was primarily rheumatological, whereas that of GRAPPA was balanced between the rheumatological and dermatological aspects of disease. In this Perspectives article, we address the similarities and differences between these two sets of recommendations and the indications for patient management.

Source:

Nature reviews rheumatology

Link to the source:

http://www.nature.com/nrrheum/journal/v12/n12/full/nrrheum.2016.183.html

Original title of article:

Management of psoriatic arthritis in 2016: A comparison of EULAR and GRAPPA recommendations

Authors:

Laure Gossec et al.

Nature reviews rheumatology
SearchTags: 
Exploratory, Psoriatic Arthritis, Skin, Joints
Log in or register to post comments